Lv3
396 积分 2023-10-17 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1天前
待确认
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1天前
已完结
OA04.06 Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001)
1天前
已完结
Challenges of small cell lung cancer heterogeneity and phenotypic plasticity
2天前
已完结
OA10.03 Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up
2天前
已完结
Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study
2天前
已完结
Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study
2天前
已完结
Analysis of lung cancer incidence, mortality trends, and smoking rates in Japan:1975–2022 with insights on the impact of COVID-19
28天前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
30天前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
30天前
已完结
皖公网安备34019202002308
